Behind the Breakthroughs

Some payers are expanding GLP-1 coverage, while others are pulling back. The access landscape has never been more fragmented—or more consequential.

AI impact over AI adoption. MEYA's Allyson Bazer shares key takeaways from ISPOR 2026 on AI in HEOR, evidence generation, and intentional innovation.

TrumpRx.gov explained: how the federal drug-pricing portal works, why it won't fix the system, who it actually helps, and four risks pharma manufacturers face.

ESG is becoming material to market access decisions, with payers and HTA bodies evaluating manufacturers on equity, transparency, and access. Here's how MEYA Health operationalizes

Diabetes Awareness Month highlights the growing impact of diabetes and the need to address barriers in prevention, management, access, and equity.

Inflation affects nearly all goods and services on the market, including drugs and healthcare products. This is the first of a series of posts...

From mental health to chronic disease, digital therapeutics are opening new paths to care—while introducing challenges around access, usability, and reimbursement.

Let's face it, the healthcare landscape is complex - developing clear and concise value communication across stakeholders is essential.

The journey from the research lab to a patient’s bedside for a drug is long, costly, and risky. Manufacturers make significant investments over many...

For years, the standard method of payment to physicians has been “fee-for-service” (FFS). This method was introduced in the 1930s and refers to...

A closer look at how tariffs and trade policy are influencing drug prices, supply chains, and access in today’s complex pharmaceutical landscape.

Explore FemTech’s $1T potential, industry shifts, key innovations, and future trends shaping women’s health.

As regulators raise the bar on clinical trial diversity, sponsors face new expectations to better reflect the populations most affected by disease.

Rapid advances in therapeutic innovation are opening new possibilities across cancer, genetic disorders, and autoimmune disease.

Healthcare payment is shifting beyond fee-for-service, with alternative models reshaping how quality, efficiency, and outcomes are measured and rewarded.

Beyond reviewing and approving drugs, the FDA plays a pivotal role in overseeing and approving medical devices, a realm defined by its innovation,...

Last week, we discussed Pride Month from the perspective of health equity in the LGBTQIA+ community. In our first Guest Blog post by Haylin Dennison,...

AI is moving healthcare beyond traditional limits, enhancing diagnostic processes, enabling tailored therapies, and accelerating discovery across the care continuum.